Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenichi Suda

Showing results (91-100 of 127) with videos related to

Pageof 13
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 31, 2017
LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating LymphocytesYayi He, Hui Yu, Leslie Rozeboom, et al.
Translational Lung Cancer Research|November 19, 2020
Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot studyShuta Ohara, Kenichi Suda, Kazuko Sakai, et al.
Cancer Science|February 5, 2016
Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancerHiroshi Mizuuchi, Kenichi Suda, Isao Murakami, et al.
Cells|September 13, 2025
Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon <i>EGFR</i> Mutations-An In Vitro StudyHana Oiki, Kenichi Suda, Akira Hamada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2015
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIsYoshihisa Kobayashi, Yosuke Togashi, Yasushi Yatabe, et al.
Molecular Cancer Therapeutics|July 31, 2012
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancerTakayuki Nakagawa, Shinji Takeuchi, Tadaaki Yamada, et al.
Cancer Research Communications|November 19, 2025
Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor AppearanceKenichi Suda, Yukihiro Yoshida, Hidenori Sato, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 10, 2021
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro ExperimentsTakamasa Koga, Kenichi Suda, Toshio Fujino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2016
Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2Masato Terashima, Yosuke Togashi, Katsuaki Sato, et al.
JTO Clinical and Research Reports|September 8, 2023
Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug TestingTakamasa Koga, Junichi Soh, Akira Hamada, et al.
Pageof 13

Showing results (91-100 of 127) with videos related to

Sort By:
Pageof 13
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 31, 2017
LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating LymphocytesYayi He, Hui Yu, Leslie Rozeboom, et al.
Translational Lung Cancer Research|November 19, 2020
Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot studyShuta Ohara, Kenichi Suda, Kazuko Sakai, et al.
Cancer Science|February 5, 2016
Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancerHiroshi Mizuuchi, Kenichi Suda, Isao Murakami, et al.
Cells|September 13, 2025
Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon <i>EGFR</i> Mutations-An In Vitro StudyHana Oiki, Kenichi Suda, Akira Hamada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2015
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIsYoshihisa Kobayashi, Yosuke Togashi, Yasushi Yatabe, et al.
Molecular Cancer Therapeutics|July 31, 2012
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancerTakayuki Nakagawa, Shinji Takeuchi, Tadaaki Yamada, et al.
Cancer Research Communications|November 19, 2025
Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor AppearanceKenichi Suda, Yukihiro Yoshida, Hidenori Sato, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 10, 2021
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro ExperimentsTakamasa Koga, Kenichi Suda, Toshio Fujino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2016
Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2Masato Terashima, Yosuke Togashi, Katsuaki Sato, et al.
JTO Clinical and Research Reports|September 8, 2023
Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug TestingTakamasa Koga, Junichi Soh, Akira Hamada, et al.
Pageof 13